Core Insights - The article discusses the evaluation of the investigational antisense drug OT-101 (also known as trabedersen) targeting TGFB2 as a treatment strategy for pancreatic ductal adenocarcinoma (PDAC) [1] - Sapu Biosciences, a subsidiary of GMP Biotechnology, collaborates with Oncotelic Therapeutics to explore TGFB2 expression levels and its promoter methylation as potential prognostic markers for PDAC [1] Research Focus - Clinical data from the OT-101 P001 PDAC study indicates that targeting TGFB2 is worth further evaluation, particularly in younger patients, with a median overall survival (OS) of 12.7 months in a subgroup with lower IL-6 levels [2] - The study's co-author, Dr. Wasif Saif, emphasized that high TGFB2 expression is significantly associated with reduced OS in patients under 65 years (median OS of 17.9 months in high expression group vs. 66.9 months in low expression group), while no such association was found in older patients [2] - High levels of TGFB2 methylation correlate with improved survival in younger patients (median OS of 66.9 months in high methylation group vs. 17.9 months in low methylation group) [2] - The use of OT-101 in clinical trials supports these findings, showing better OS in younger patients compared to untreated controls [2]